Shopping Cart
- Remove All
Your shopping cart is currently empty
Azelaprag
Catalog No. T14390Cas No. 2049980-18-7
Alias AMG 986
Azelaprag (AMG 986) is an effective small-molecule apelin receptor agonist. Azelaprag can be used to treat neurological diseases and cardiovascular diseases.
Azelaprag
Catalog No. T14390Alias AMG 986Cas No. 2049980-18-7
Azelaprag (AMG 986) is an effective small-molecule apelin receptor agonist. Azelaprag can be used to treat neurological diseases and cardiovascular diseases.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $396 | In Stock | |
| 5 mg | $1,180 | In Stock | |
| 10 mg | $1,530 | In Stock | |
| 25 mg | $2,160 | In Stock | |
| 50 mg | $2,800 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $1,380 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Azelaprag"
CMF019
T108431586787-08-7In house
CMF019 is a potent agonist of the Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ (pKis: 8.58, 8.49, and 8.71 for the human, rat, and mouse).
- $122
Size
QTY
ELA-11 (human) acetate(1784687-32-6 free base)
TP1922L1
ELA-11 (human) acetate high affinity apelin receptor agonist (Ki = 14 nM). Bioactive fragment of ELA-32. Inhibits forskolin-induced cAMP production and stimulates β-arrestin recruitment in vitro.
- $133
Size
QTY
Apelin-12 acetate
Apelin-12 acetate (229961-08-4 Free base)
T39823L
Apelin-12 acetate possesses a high affinity to orphan receptor APJ receptor. Apelin-12 acetate inhibits the JNK and p38 MAPK signaling pathway of the apoptosis-related MAPKs family, thus offering protection to neurons.
- $228
Size
QTY
[Pyr1]-Apelin-13
Cited
[pGlu1]-Apelin-13
TP1260217082-60-5
[Pyr1]-Apelin-13 ([pGlu1]-Apelin-13) is a potent and selective endogenous Apelin receptor (APJ) agonist.
- $89
Size
QTY
CitedAM-8123
T394422049973-02-4In house
AM-8123 is an orally available nonpeptide APJ agonist.AM-8123 reduces collagen load and improves cardiac function. AM-8123 ameliorates myocardial infarction in rats and can be used to study cardiovascular diseases such as heart failure.
- $293
Size
QTY
ML221 Cited
T4390877636-42-5
ML221 is a potent apelin /APJ functional antagonist, inhibiting apelin-13-mediated activation of APJ, with IC50s of 0.70 μM in the cAMP assay, and 1.75 μM in the β-arrestin assay, and EC80 of 10 nM in both assays.
- $50
Size
QTY
CitedALX 40-4C acetate
ALX 40-4C acetate(143413-49-4 free base)
TP1364L
ALX 40-4C acetate is a CXCR4 inhibitor of the chemokine receptor (Ki = 1 μM) and suppresses the replication of X4 strains of HIV-1. ALX 40-4C acetate is an antagonist of the APJ receptor (IC50 = 2.9 μM).
- $221
Size
QTY
BMS-986224
BMS 986224
T394482055200-88-7
BMS-986224 is an orally active, potent, and selective APJ receptor agonist. BMS-986224 has the potential to study heart failure.
- $399
Size
QTY
(2R,3S)-Azelaprag
T14390L2049979-31-7In house
(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide is an Apelin receptor agonist with an EC50 for Apelin receptors of 0.012 µM.(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5- methylpyrimidin-2-yl)butane-2-sulfonamide is used in the treatment of heart failure, atherosclerosis, obesity, diabetes mellitus, amyotrophic lateral sclerosis, coronary artery disease, hypertension, stroke and myocardial infarction.
- $2,500
Size
QTY
ELA-14(human) acetate
ELA-14(human) acetate (1886973-05-2 free base)
TP1923L1
ELA-14(human) acetate is a fragment of ELA that binds to APJ, activates the Gαi1 and β-arrestin-2 signaling pathways, and induces receptor internalization similarly to its parent endogenous peptide.
- $57
Size
QTY
(Ala13)-Apelin-13 acetate
T35374L
(Ala13)-Apelin-13 acetate, an APJ antagonist, modulates CRF-induced enhanced colonic motility, visceral sensation, and gut barrier.
- $118
Size
QTY
Select Batch
Purity:99.60%
ee:100%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Azelaprag (AMG 986) is an effective small-molecule apelin receptor agonist. Azelaprag can be used to treat neurological diseases and cardiovascular diseases. |
| Targets&IC50 | RAGE:12.7 ± 7.6 nM (kd) |
| In vivo | In the transgenic Alzheimer's disease animal model (tgAPPSwedish/London), azeliragon (5 mg/day) reduces Aβ plaque deposition, decreases overall Aβ burden while increasing Aβ levels in plasma, lowers sAPPβ and increases sAPPα levels, reduces inflammatory cytokines, slows cognitive decline, and improves cerebral blood flow.[1] |
| Alias | AMG 986 |
| Molecular Weight | 523.61 |
| Formula | C25H29N7O4S |
| Cas No. | 2049980-18-7 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (114.59 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Azelaprag | purchase Azelaprag | Azelaprag cost | order Azelaprag | Azelaprag chemical structure | Azelaprag in vivo | Azelaprag formula | Azelaprag molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.